76,060 results match your criteria systemic lupus


Genetic Polymorphisms in Patients With Systemic Lupus Erythematosus and Jaccoud Arthropathy: A Pilot Study.

J Clin Rheumatol 2021 Sep;27(6S):S193-S197

Serviço de Reumatologia do Hospital Universitário Professor Edgard Santos-Universidade Federal da Bahia.

Introduction: Jaccoud arthropathy (JA) is a nonerosive and deforming arthropathy experienced frequently by patients with systemic lupus erythematosus (SLE). Although genetic polymorphisms are associated with SLE development, the association between genetic polymorphisms and JA has not been studied to date. The main objective of this study was to evaluate an association between HLA, STAT4, IRF5, and BLK polymorphisms and the presence of JA in Brazilian individuals with SLE. Read More

View Article and Full-Text PDF
September 2021

Expression signature of inflammation-associated long non-coding RNAs in adult-onset Still's disease.

Clin Exp Rheumatol 2021 Sep 13. Epub 2021 Sep 13.

College of Medicine, China Medical University, Taichung; Translational Medicine Laboratory, Rheumatology and Immunology Centre, China Medical University Hospital, Taichung; Rheumatology and Immunology Centre, China Medical University Hospital, Taichung, and Ph.D. Program in Translational Medicine and Rong Hsing Research Centre for Translational Medicine, National Chung Hsing University, Taichung, Taiwan.

Objectives: Adult-onset Still's disease (AOSD) is a rare and complex inflammatory disease with unclear immunopathogenesis. This study aims to investigate the expression signature of inflammation-associated long non-coding RNAs (lncRNAs) in AOSD and to evaluate its utility for disease diagnosis and prognostication.

Methods: Expression levels of lncRNAs MIAT, THRIL, NTT, RMRP, PACERR and NEAT1 in peripheral blood mononuclear cells (PBMCs) from treatment-naïve AOSD patients and healthy donors were assessed by quantitative real-time PCR and logistic regression analysis. Read More

View Article and Full-Text PDF
September 2021

Identification of causal metabolites related to multiple autoimmune diseases.

Hum Mol Genet 2021 Sep 15. Epub 2021 Sep 15.

Center for Genetic Epidemiology and Genomics, School of Public Health, Medical College of Soochow University, Suzhou, China.

Object: Observational studies provide evidence that metabolites may be involved in the development of autoimmune diseases (ADs), but whether it is causal is still unknown.

Methods: Based on the large-scale GWAS summary statistics, two-sample Mendelian randomization (MR) was performed to evaluate the causal association between human serum metabolites and multiple ADs, which were inflammatory bowel disease (IBD), ulcerative Colitis (UC), crohn's disease (CD), rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), type 1 diabetes (T1D), multiple sclerosis (MS), primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). Comprehensive sensitive analysis was used to validate the robustness of MR results and multivariable MR analysis was conducted to avoid potential pleiotropic effect of other complex traits. Read More

View Article and Full-Text PDF
September 2021

Atypical presentation of pediatric antiphospholipid syndrome.

JAAD Case Rep 2021 Oct 18;16:50-52. Epub 2021 Aug 18.

Las Vegas Dermatology, Las Vegas, Nevada.

View Article and Full-Text PDF
October 2021

Phenotypic characterization of patients with activated PI3Kδ syndrome 1 presenting with features of systemic lupus erythematosus.

Genes Dis 2021 Nov 30;8(6):907-917. Epub 2020 Apr 30.

National Clinical Research Center for Child Health and Disorders (Chongqing), Children's Hospital ofChongqing Medical University, Chongqing, 400014, PR China.

Activated phosphoinositide 3-kinase δ syndrome 1 (APDS1) is a primary immunodeficiency disease caused by gain-of-function mutations in . Clinical features of autoimmune disease have been reported in patients with APDS1. In this study, we reported three patients with APDS1 presenting with systemic lupus erythematosus (SLE) phenotype. Read More

View Article and Full-Text PDF
November 2021

Kikuchi-Fujimoto Disease: A Rare Cause of Cervical Lymphadenopathy.

Cureus 2021 Aug 9;13(8):e17021. Epub 2021 Aug 9.

Psychiatry, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.

Kikuchi-Fujimoto disease (KFD) is a rare benign disease, clinically characterized by fever and tender cervical lymphadenopathy affecting the posterior cervical lymph nodes. This disease is usually accompanied by night sweats, rashes, and headaches. It generally affects young individuals, especially females, of Oriental-Asian origin. Read More

View Article and Full-Text PDF

Levels of the macrophage migration inhibitory factor and polymorphisms in systemic lupus erythematosus: a meta-analysis.

Arch Med Sci 2021 31;17(5):1232-1240. Epub 2019 May 31.

Department of Epidemiology and Biostatistics, School of Public Health and Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Medical University, Hefei, Anhui, China.

Introduction: Several published results have established variations in respect to plasma/serum macrophage migration inhibitory factor (MIF) levels and gene polymorphisms with systemic lupus erythematosus (SLE). This study gave a more concise estimation on the MIF levels for SLE patients and established the association between MIF polymorphisms and SLE.

Material And Methods: All articles were searched from PubMed, Embase, Web of Science, Wan-Fang, Chinese Biological Medical Literature, and China National Knowledge Infrastructure up to 6 October 2017, with no language restriction. Read More

View Article and Full-Text PDF

AIM2 deficiency in B cells ameliorates systemic lupus erythematosus by regulating Blimp-1-Bcl-6 axis-mediated B-cell differentiation.

Signal Transduct Target Ther 2021 Sep 14;6(1):341. Epub 2021 Sep 14.

Department of Dermatology, Second Xiangya Hospital, Central South University, Hunan Key Laboratory of Medical Epigenomics, Changsha, Hunan, China.

Absent in melanoma 2 (AIM2) has been reported to be a component of inflammasomes in innate immune cells. Surprisingly, AIM2 is expressed by B cells, and higher AIM2 expression is observed in the B cells from lupus patients. To date, the inflammasome-independent function of AIM2 in B cells remains unclear. Read More

View Article and Full-Text PDF
September 2021

Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015.

Lupus Sci Med 2021 Sep;8(1)

BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.

Objective: To assess the economic burden of patients with SLE by disease severity in the USA 1 year before and after diagnosis.

Methods: Patients aged ≥18 years with a first SLE diagnosis (index date) between January 2005 and December 2014 were identified from administrative commercial claims data linked to electronic medical records (EMRs). Disease severity during the year after diagnosis was classified as mild, moderate, or severe using claims-based algorithms and EMR data. Read More

View Article and Full-Text PDF
September 2021

From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift?

Ann Rheum Dis 2021 Sep 14. Epub 2021 Sep 14.

Pôle de Pathologies Rhumatismales Inflammatoires et Systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium

The current treatment paradigm in lupus nephritis consists of an initial phase aimed at inducing remission and a subsequent remission maintenance phase. With this so-called sequential treatment approach, complete renal response is achieved in a disappointing proportion of 20-30% of the patients within 6-12 months, and 5-20% develop end-stage kidney disease within 10 years. Treat-to-target approaches are detained owing to uncertainty as to whether the target should be determined based on clinical, histopathological, or immunopathological features. Read More

View Article and Full-Text PDF
September 2021

The citrullinated/native index of autoantibodies against hnRNP-DL predicts an individual "window of treatment success" in RA patients.

Arthritis Res Ther 2021 Sep 14;23(1):239. Epub 2021 Sep 14.

Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Charite Campus Mitte, Rheumatologisches Forschungslabor - AG Skriner, Chariteplatz 1 (intern Virchowweg 11, 5.OG, R011), 10117, Berlin, Germany.

Background: There is a need for biomarker to identify patients "at risk" for rheumatoid arthritis (risk-RA) and to better predict the therapeutic response and in this study we tested the hypothesis that novel native and citrullinated heterogeneous nuclear ribonucleoprotein (hnRNP)-DL autoantibodies could be possible biomarkers.

Methods: Using protein macroarray and ELISA, epitope recognition against hnRNP-DL was analysed in sera from different developed RA disease and diagnosed SLE patients. Toll-like receptor (TLR) 7/9 and myeloid differentiation primary response gene 88 (MyD88)-dependency were studied in sera from murine disease models. Read More

View Article and Full-Text PDF
September 2021

Gut microbiota mediated the therapeutic efficacies and the side effects of prednisone in the treatment of MRL/lpr mice.

Arthritis Res Ther 2021 Sep 14;23(1):240. Epub 2021 Sep 14.

Institute of Basic Research in Clinical Medicine, College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, 310053, China.

Background: Growing evidences indicate that the alterations in gut microbiota are associated with the efficacy of glucocorticoids (GCs) in the treatment of systemic lupus erythematosus (SLE). However, there is no evidence to prove whether gut microbiota directly mediates the effects of GCs.

Methods: Using the MRL/lpr mice, this study firstly addressed the effects of three doses of prednisone on gut microbiota. Read More

View Article and Full-Text PDF
September 2021

Intravenous immunoglobulin in macrophage activation syndrome associated with systemic lupus erythematosus.

Rev Med Inst Mex Seguro Soc 2020 09 1;58(5):634-643. Epub 2020 Sep 1.

Instituto Mexicano del Seguro Social, Centro Médico Nacional La Raza, Hospital de Especialidades "Dr. Antonio Fraga Mouret", Departamento de Hematología. Ciudad de México, México.

Background: The hemophagocytic lymphohistiocytosis is a disease with a potential fatal evolution, caused by the activation of macrophages and histiocytes with hemophagocytosis in bone marrow and other reticuloendothelial systems, triggered by a defect in the T lymphocyte when stimulating the production of interleukin 1-beta, interleukin 6, interferon-gamma and tumor necrosis factor-alpha that promote macrophage activation. This condition presents with fever, cytopenias, splenomegaly, hemophagocytosis in bone marrow, hypertriglyceridemia and hypofibrinogenemia, in the context of an infectious, neoplastic or autoimmune disease. The objective of this article is to describe the utility of intravenous immunoglobulin (IVIg) in patients unable to receive immunosuppressive treatment. Read More

View Article and Full-Text PDF
September 2020

Systemic Lupus Erythematosus and Pregnancy: a Portuguese Case-Control Study.

Clin Rev Allergy Immunol 2021 Sep 14. Epub 2021 Sep 14.

Maternal Fetal Unit, Centro Materno Infantil Do Norte, Centro Hospitalar Universitário Do Porto, Oporto, Portugal.

Pregnancy in systemic lupus erythematosus (SLE) patients is associated with an increased risk of adverse outcomes. During pregnancy, SLE patients have a higher rate of miscarriage, stillbirth, preterm delivery, fetal growth restriction, or hypertensive disorders of pregnancy. To date, only a few case-control studies were published with the purpose to evaluate the magnitude of risk associated with pregnancy in lupus patients. Read More

View Article and Full-Text PDF
September 2021

Association between complement gene polymorphisms and systemic lupus erythematosus: a systematic review and meta-analysis.

Clin Exp Med 2021 Sep 14. Epub 2021 Sep 14.

Rheumatology Research Center, Shariati Hospital, Tehran University of Medical Sciences, Kargar Ave., Tehran, Iran.

Complement dysfunction results in impaired ability in clearing apoptotic cell debris that may stimulate autoantibody production in systemic lupus erythematosus (SLE). Herein, we provided a comprehensive search to find and meta-analyze any complement gene polymorphisms associated with SLE. The ITGAM, C1q, and MBL gene polymorphisms were included in this meta-analysis to reveal the exact association with SLE risk. Read More

View Article and Full-Text PDF
September 2021

Telitacicept as a BLyS/APRIL dual inhibitor for autoimmune disease.

Immunopharmacol Immunotoxicol 2021 Sep 14:1-8. Epub 2021 Sep 14.

Department of Oral and Maxillofacial Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.

The pathogenic roles for B cells in autoimmunity include produce pathogenic autoantibodies and modulate immune responses the production of cytokines and chemokines. The B lymphocyte stimulator BLyS (also known as B-cell-activating factor, BAFF) and APRIL (a proliferation-inducing ligand) are critical factors in the maintenance of the B-cell pool and humoral immunity, namely BLyS modulates the differentiation and maturation of immature B cell, while APRIL modulates the function and survival of long-lived plasma cell, which plays a prominent role in the pathogenesis of autoimmune diseases. Telitacicept is a novel recombinant fusion protein of both the ligand-binding domain of the TACI receptor and the Fc component of human IgG and which is a BLyS/APRIL dual inhibitor. Read More

View Article and Full-Text PDF
September 2021

+869 T > C (rs1800470) variant is independently associated with susceptibility, laboratory activity, and TGF-β1 in patients with systemic lupus erythematosus.

Autoimmunity 2021 Sep 14:1-7. Epub 2021 Sep 14.

Department of Pathology, Clinical Analysis and Toxicology, Laboratory of Research in Applied Immunology, State University of Londrina, Londrina, Brazil.

The aim of this study was to evaluate the association of the +869 T > C (rs1800470) and -509 C > T (rs1800469) variants, individually or in haplotypes structure, with susceptibility, autoantibodies, disease activity, and TGF-β1 plasma levels in patients with systemic lupus erythematosus (SLE). The study included 203 patients with SLE and 165 healthy controls. variants were determined by real-time polymerase chain reaction (qPCR). Read More

View Article and Full-Text PDF
September 2021

Optimizing reproductive health management in lupus and Sjogren's syndrome.

Curr Opin Rheumatol 2021 Sep 13. Epub 2021 Sep 13.

Center for Women's Health Research and Innovation (CWHRI) Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology & Reproductive Sciences, Pittsburgh, Pennsylvania Division of Rheumatology and Immunology, Department of Medicine, Duke University, Durham, North Carolina, USA.

Purpose Of Review: People with childbearing capacity who are diagnosed with systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS) have specific and important reproductive health considerations.

Recent Findings: Recommendations from the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR) provide rheumatologists and other clinicians with guidance for reproductive health management of patients with rheumatic diseases. Patient-centered reproductive health counseling can help clinicians to operationalize the EULAR and ACR guidelines and enhance patient care. Read More

View Article and Full-Text PDF
September 2021

Late-Onset Systemic Lupus Erythematosus Associated with Autoimmune Hemolytic Anemia and Sixth Cranial Nerve Palsy.

Am J Case Rep 2021 Sep 14;22:e932959. Epub 2021 Sep 14.

Department of Rheumatology, Okinawa Chubu Hospital, Uruma, Okinawa, Japan.

BACKGROUND Patients with late-onset systemic lupus erythematosus (SLE) do not present with typical SLE symptoms or serology, and this can lead to a major delay in diagnosis. We report a complex case of an older woman who developed autoimmune hemolytic anemia and sixth cranial nerve palsy that posed considerable challenges in diagnosing late-onset SLE. CASE REPORT A 78-year-old Japanese woman presented with polyarthritis associated with generalized fatigue for 2 months, who later developed diplopia. Read More

View Article and Full-Text PDF
September 2021

Immune disorders associated with juvenile recurrent chronic parotitis.

An Pediatr (Engl Ed) 2021 Sep 10. Epub 2021 Sep 10.

Servicio de Pediatría, Hospital Universitari i Politècnic La Fe, Valencia, Spain. Electronic address:

Introduction: Juvenile recurrent chronic parotitis (JRCP) is a rare disease of unknown cause. There is a growing interest in its autoimmune aetiology and its relationship with dysfunctions of cellular and humoral immunity, although there is no agreed protocol for complementary investigations for its study. A consecutive series of cases is presented where the immune alterations and associated autoimmune disorders are investigated, proposing a study algorithm. Read More

View Article and Full-Text PDF
September 2021

Ranking the Importance of Their Own Diseases: A Positioning Analysis in Rheumatic Patients and Their Proxies.

Reumatol Clin 2021 Sep 10. Epub 2021 Sep 10.

Unidad de Investigación en Enfermedades Crónico-Degenerativas, Guadalajara, Mexico; Universidad Autónoma de Guadalajara, Guadalajara, Mexico. Electronic address:

Introduction/objective: To assess the positioning that patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), ankylosing spondylitis (AS) and their proxies give to their diseases.

Methods: Subjects completed a self-administered questionnaire to rank 11 diseases from "worst" to "least bad". Then they defined the "worst" disease and ranked 10 diseases from highest to lowest importance from a list including "my rheumatic disease/my relative's disease". Read More

View Article and Full-Text PDF
September 2021

Prognostic and Diagnostic Values of Novel Serum and Urine Biomarkers in Lupus Nephritis: A Systematic Review.

Am J Nephrol 2021 Aug 13;52(7):559-571. Epub 2021 Aug 13.

Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Aosta Valley Network for Rare Diseases, S. Giovanni Bosco Hospital, University of Turin, Turin, Italy.

Introduction: While renal biopsy remains the gold standard for diagnosing lupus nephritis (LN), the prognostic and diagnostic role of non-invasive biomarkers for LN is currently debated.

Methods: Available studies published in last 5 years (2015-2020) assessing the diagnostic and prognostic value of urinary and/or serological biomarkers in subjects with LN were analyzed in this systematic review.

Results: Eighty-five studies were included (comprehending 13,496 patients with systemic lupus erythematosus [SLE], 8,872 LN, 487 pediatric LN, 3,977 SLE but no LN, 160 pediatric SLE but no LN and 7,679 controls). Read More

View Article and Full-Text PDF

Tetraspanin CD53 modulates lymphocyte trafficking but not systemic autoimmunity in Lyn-deficient mice.

Immunol Cell Biol 2021 Sep 12. Epub 2021 Sep 12.

Centre for Inflammatory Diseases, Monash University, Department of Medicine, Monash Medical Centre, 246 Clayton Rd, Clayton, VIC, Australia.

The leukocyte-restricted tetraspanin CD53 has been shown to promote lymphocyte homing to lymph nodes and myeloid cell recruitment to acutely inflamed peripheral organs, and accelerate the onset of immune-mediated disease. However, its contribution in the setting of chronic systemic autoimmunity has not been investigated. We made use of the Lyn autoimmune model, generating Cd53 Lyn mice, and compared trafficking of immune cells into secondary lymphoid organs and systemic autoimmune disease development with mice lacking either gene alone. Read More

View Article and Full-Text PDF
September 2021

Clinico-Histological Features of Thrombotic Microangiopathy in Renal Biopsies: A Retrospective Study.

Turk Patoloji Derg 2021 May 17. Epub 2021 May 17.

Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research Karaikal, PUDUCHERRY, INDIA.

Objective: Thrombotic microangiopathy (TMA) is often first detected on a renal biopsy performed for renal manifestations. Apart from hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura, there are various secondary conditions associated with TMA. This study analyzes the clinico-pathological spectrum, etiological factors and renal outcome of TMA diagnosed on renal biopsy. Read More

View Article and Full-Text PDF

Treatment Outcomes of Proliferative vs. Non-proliferative Adult Lupus Nephritis: A 10-Year Follow-Up.

Cureus 2021 Aug 6;13(8):e16955. Epub 2021 Aug 6.

Nephrology Department, Urology & Nephrology Center, Mansoura, EGY.

Introduction Systemic lupus erythematosus (SLE) is a systemic disease with clinically heterogeneous outcomes. Lupus nephritis (LN) is a common complication of SLE. LN impacts clinical SLE outcomes both directly, in the form of target organ damage, and indirectly, through the adverse effects of immunosuppressive therapy. Read More

View Article and Full-Text PDF

Posterior Reversible Encephalopathy in Undiagnosed Systemic Lupus Erythematosus: A Rare Case Report.

Cureus 2021 Aug 6;13(8):e16945. Epub 2021 Aug 6.

Family Medicine, Caribbean Medical University, Des Plaines, USA.

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder known to affect the nervous system by direct neuronal damage, vasculitis, or pathologic mechanisms indirectly induced by immune mechanisms related to the production and deposition of immune complexes. SLE has a wide range of clinical manifestations due to the involvement of almost every organ system of the body. SLE presents with serositis, mucositis, arthralgia, glomerulopathy, hematological, cutaneous, and hematological manifestations. Read More

View Article and Full-Text PDF

A Case of Systemic Lupus Erythematosus in a Patient Presenting with Libman-Sacks Endocarditis.

Case Rep Cardiol 2021 31;2021:5573141. Epub 2021 Aug 31.

Department of Cardiac Sciences, King Faisal Cardiac Center, National Guard Hospital, Jeddah, Saudi Arabia.

Background: Libman-Sacks endocarditis (LSE) is a rare cardiovascular manifestation of systemic lupus erythematosus/antiphospholipid syndrome that is described as a sterile verrucous nonbacterial vegetative lesion. These lesions can cause progressive damage to the heart valves leading to valve surgery. The most common valves to be affected are the aortic and mitral valves. Read More

View Article and Full-Text PDF

Mitochondrial Nucleic Acid as a Driver of Pathogenic Type I Interferon Induction in Mendelian Disease.

Front Immunol 2021 26;12:729763. Epub 2021 Aug 26.

Université de Paris, Imagine Institute, Laboratory of Neurogenetics and Neuroinflammation, Inserm UMR 1163, Paris, France.

The immune response to viral infection involves the recognition of pathogen-derived nucleic acids by intracellular sensors, leading to type I interferon (IFN), and downstream IFN-stimulated gene, induction. Ineffective discrimination of self from non-self nucleic acid can lead to autoinflammation, a phenomenon implicated in an increasing number of disease states, and well highlighted by the group of rare genetic disorders referred to as the type I interferonopathies. To understand the pathogenesis of these monogenic disorders, and polyfactorial diseases associated with pathogenic IFN upregulation, such as systemic lupus erythematosus and dermatomyositis, it is important to define the self-derived nucleic acid species responsible for such abnormal IFN induction. Read More

View Article and Full-Text PDF

SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic.

Front Immunol 2021 27;12:724047. Epub 2021 Aug 27.

Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden.

Objectives: Impact of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic on individuals with arthritis has been highlighted whereas data on other rheumatic diseases, e.g., systemic lupus erythematosus (SLE), are scarce. Read More

View Article and Full-Text PDF
September 2021